The　existing　therapies　for　cancer　are　not　remote　satisfactory　due　to　drug-resistance　in　tumors　that　are　malignant.　There　is　a　pressing　necessity　to　take　a　step　forward　to　develop　innovative　therapies　that　can　complement　current　ones.　Multiple　investigations　have　demonstrated　that　ferroptosis　therapy,　a　non-apoptotic　modality　of　programmed　cell　death,　has　tremendous　potential　in　face　of　multiple　crucial　events,　such　as　drug　resistance　and　toxicity　in　aggressive　malignancies.　Recently,　ferroptosis　at　the　crosswalk　of　chemotherapy,　materials　science,　immunotherapy,　tumor　microenvironment,　and　bionanotechnology　has　been　presented　to　elucidate　its　therapeutic　feasibility.　Given　the　burgeoning　progression　of　ferroptosis-based　nanomedicine,　the　newest　advancements　in　this　field　at　the　confluence　of　ferroptosis-inducers,　nanotherapeutics,　along　with　tumor　microenvironment　are　given　an　overview.　Here,　the　signaling　pathways　of　ferroptosis-related　were　first　talked　about　briefly.　The　emphasis　discussion　was　placed　on　the　pharmacological　mechanisms　and　the　nanodrugs　design　of　ferroptosis　inducing　agents　based　on　multiple　distinct　metabolism　pathways.　Additionally,　a　comprehensive　overview　of　the　action　mechanisms　by　which　the　tumor　microenvironment　influences　ferroptosis　was　elaborately　descripted.　Finally,　some　limitations　of　current　researches　and　future　research　directions　were　also　deliberately　discussed　to　provide　details　about　therapeutic　avenues　for　ferroptosis-related　diseases　along　with　the　design　of　anti-drugs.